Cerebellar Intermittent Theta Burst Stimulation for Post-Stroke Cognitive Impairment: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500115603

Enrollment

Unknown

Registered

2025-12-29

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-stroke cognitive impairment

Interventions

Experimental group:Cerebellar iTBS+Cognitive Rehabilitation Training

Control group:sham iTBS+Cognitive Rehabilitation Training

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with stroke confirmed by neuroimaging (MRI/CT); 2. Age range: 35-75 years old; 3. Meet the criteria for AHA/ASA diagnosis of cognitive impairment after stroke; 4. Patients with mild to moderate cognitive impairment as assessed by the Mini-Mental State Examination (MMSE) scale. 5. Patients with a post-stroke duration ranging from 3 to 12 months. 6. Right-handedness. 7. Participants were well-informed about the treatment procedures and be willing to assign, or have their legal guardians to assign the consent.

Exclusion criteria

Exclusion criteria: 1. Presence of comorbid neurological disorders other than stroke. 2. Contraindications to transcranial magnetic stimulation (TMS) including but not limited to: implanted cardiac pacemakers, intracranial metallic implants, cranial defects, or documented history of epilepsy. 3. Concurrent severe dysfunction of vital organ systems (e.g., cardiac, pulmonary, hepatic, or renal insufficiency) or other severe systemic comorbidities. 4. Diagnosis of non-stroke-related conditions that may confound cognitive function assessments. 5. Participants with other etiologies of vascular cognitive impairment (e.g., subcortical ischemic vascular cognitive impairment, multi-infarct dementia, mixed dementia) were excluded. 6. Participants presented with dysarthria.

Design outcomes

Primary

Measure	Time frame
Montreal cognitive assessment;	—

Secondary

Measure	Time frame
Hamilton depression scale;Boston naming test;Oxford cognitive screen;functional near-infrared spectroscopy;mini-mental state examination;modified Barthel index;Hamilton anxiety scale;	—

Countries

China

Contacts

Public ContactChangyue Gao

Army Medical Center of PLA

1435849215@qq.com+86 23 6874 6181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026